251 related articles for article (PubMed ID: 32500026)
1. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
3. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
Front Oncol; 2019; 9():663. PubMed ID: 31380290
[TBL] [Abstract][Full Text] [Related]
4. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
5. Two effective models based on comprehensive lipidomics and metabolomics can distinguish BC versus HCs, and TNBC versus non-TNBC.
Jin Y; Fan S; Jiang W; Zhang J; Yang L; Xiao J; An H; Ren L
Proteomics Clin Appl; 2023 May; 17(3):e2200042. PubMed ID: 36443927
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
7. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
8. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
9. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; He L; Zhang W; Wang Y; Li H; Fan L; Tsang SX; Zhang Y; Sun W
Front Oncol; 2020; 10():1507. PubMed ID: 33014794
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
12. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
13. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
Lin L; Huang Z; Gao Y; Chen Y; Hang W; Xing J; Yan X
Proteomics; 2012 Aug; 12(14):2238-46. PubMed ID: 22685041
[TBL] [Abstract][Full Text] [Related]
14. Label-free screening of common urinary system tumors from blood plasma based on surface-enhanced Raman spectroscopy.
Xu Q; Li T; Lin J; Wu X
Photodiagnosis Photodyn Ther; 2024 Feb; 45():103900. PubMed ID: 38081568
[TBL] [Abstract][Full Text] [Related]
15. Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B.
Yang Y; Xu J; Zhang Q
Oncol Lett; 2018 May; 15(5):7923-7933. PubMed ID: 29725479
[TBL] [Abstract][Full Text] [Related]
16. Plasma metabolomics and lipidomics reveal potential novel biomarkers in early gastric cancer: An explorative study.
Wang F; Pang R; Zhao X; Zhou B; Tian Y; Ma Y; Rong L
Int J Biol Markers; 2024 Jun; ():3936155241258780. PubMed ID: 38859802
[TBL] [Abstract][Full Text] [Related]
17. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer.
Zhou Y; Song R; Zhang Z; Lu X; Zeng Z; Hu C; Liu X; Li Y; Hou J; Sun Y; Xu C; Xu G
Anal Bioanal Chem; 2016 Sep; 408(24):6741-9. PubMed ID: 27473428
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
19. UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease.
Gong Y; Zhang P; Liu Z; Li J; Lu H; Wang Y; Qiu B; Wang M; Fei Y; Chen H; Peng L; Li J; Zhou J; Shi Q; Zhang X; Shen M; Zeng X; Zhang F; Zhang W
Rheumatology (Oxford); 2021 Jul; 60(7):3252-3261. PubMed ID: 33341881
[TBL] [Abstract][Full Text] [Related]
20. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
